Gilead Says New Hepatitis Drug Does Not Infringe Merck IP

Law360, New York (September 3, 2013, 3:26 PM EDT) -- Gilead Sciences Inc. has asked a federal court in California to issue a declaratory judgment that its hepatitis C drug would not infringe two Merck & Co. Inc. patents, or to deem the patents invalid, according to a suit filed Friday.

Foster City, Calif.-based Gilead said it has received calls and an email from Merck offering to license the rights to the two patents covering Merck's Victrelis hepatitis C drug for an allegedly untenable amount, in an attempt to prevent Gilead’s competing medication from hitting the...
To view the full article, register now.